Happy Amarin day
Six years and what feels like an eternity ago, a panel of FDA advisers recommended against expanding the use of Vascepa, Amarin’s only approved drug. Today, the company returns, armed with loads more data and the chance to turn its commercially quiet cardiovascular pill into a blockbuster product.
The world at large has had a year to prod, probe, and perseverate over Amarin’s claim that Vascepa can reduce the risk of heart attacks and strokes over the long run. But the words — and final vote — of the FDA’s experts will go a long way in predicting how the agency itself might rule.
Starting at 8 a.m. ET today, we’ll hear from both Amarin and the FDA on the merits of Vascepa. We’ve got STAT’s Adam Feuerstein and Matt Herper locked in a room someplace to provide updates and analysis from the hearing, and you can follow along with them here.
The world at large has had a year to prod, probe, and perseverate over Amarin’s claim that Vascepa can reduce the risk of heart attacks and strokes over the long run. But the words — and final vote — of the FDA’s experts will go a long way in predicting how the agency itself might rule.
Starting at 8 a.m. ET today, we’ll hear from both Amarin and the FDA on the merits of Vascepa. We’ve got STAT’s Adam Feuerstein and Matt Herper locked in a room someplace to provide updates and analysis from the hearing, and you can follow along with them here.
No hay comentarios:
Publicar un comentario